Influenza vaccine effectiveness in Europe and the birth cohort effect against influenza A(H1N1)pdm09: VEBIS primary care multicentre study, 2023/24

IntroductionInfluenza A(H1N1)pdm09, A(H3N2) and B/Victoria viruses circulated in Europe in 2023/24, with A(H1N1)pdm09 dominance. First influenza infections in childhood may lead to different vaccine effectiveness (VE) in subsequent years.AimThe VEBIS primary care network estimated influenza VE in Eu...

Descripción completa

Detalles Bibliográficos
Autores: Kissling, Esther, Maurel, Marine, Pozo, Francisco, Pérez-Gimeno, Gloria, Buda, Silke, Sève, Noémie, Domegan, Lisa, Hooiveld, Mariëtte, Oroszi, Beatrix, Martínez-Baz, Iván, Guiomar, Raquel, Latorre-Margalef, Neus, Mlinarić, Ivan, Lazar, Mihaela, Gimenez Duran, Jaume, Dürrwald, Ralf, Enouf, Vincent, McKenna, Adele, de Lange, Marit, Túri, Gergő, Trobajo-Sanmartín, Camino, Gomez, Verónica, Samuelsson Hagey, Tove, Višekruna Vučina, Vesna, Cherciu, Maria Carmen, García Vazquez, Miriam, Erdwiens, Annika, Masse, Shirley, Bennett, Charlene, Meijer, Adam, Kristóf, Katalin, Castilla, Jesús, Rodrigues, Ana Paula, Kurečić Filipović, Sanja, Ivanciuc, Alina Elena, Bacci, Sabrina, Kaczmarek, Marlena
Tipo de recurso: artículo
Fecha de publicación:2025
País:España
Institución:Conselleria de Salut i Consum del Govern de les Illes Balears
Repositorio:Docusalut
Idioma:inglés
OAI Identifier:oai:docusalut.com:20.500.13003/25248
Acceso en línea:https://hdl.handle.net/20.500.13003/25248
Access Level:acceso abierto
Palabra clave:Adolescent
Adult
Aged
Child
Child, Preschool
Europe
Female
Humans
Infant
Influenza A Virus, H1N1 Subtype
Influenza B virus
Influenza Vaccines
Influenza, Human
Male
Middle Aged
Primary Health Care
Vaccination
Vaccine Efficacy
Young Adult
Adolescente
Adulto
Anciano
Niño
Preescolar
Europa (Continente)
Femenino
Humanos
Lactante
Subtipo H1N1 del Virus de la Influenza A
Virus de la Influenza B
Vacunas contra la Influenza
Gripe Humana
Masculino
Persona de Mediana Edad
Atención Primaria de Salud
Vacunación
Eficacia de las Vacunas
Adulto Joven
Influenza
case-control study
imprinting
influenza vaccines
multicentre study
vaccine effectiveness
Descripción
Sumario:IntroductionInfluenza A(H1N1)pdm09, A(H3N2) and B/Victoria viruses circulated in Europe in 2023/24, with A(H1N1)pdm09 dominance. First influenza infections in childhood may lead to different vaccine effectiveness (VE) in subsequent years.AimThe VEBIS primary care network estimated influenza VE in Europe using a multicentre test-negative study.MethodsPrimary care practitioners collected information and specimens from patients consulting with acute respiratory infection. We estimated VE against influenza (sub)type and clade, by age group and by year of age for A(H1N1)pdm09, using logistic regression.ResultsWe included 29,958 patients, with 3,054, 1,053 and 311 influenza A(H1N1)pdm09, A(H3N2) and B cases, respectively. All-age VE against influenza A(H1N1)pdm09 was 52% (95% CI: 44-59). By year of age, VE was 27% (95% CI: -2 to 47) at 44 years with peaks at 72% (95% CI: 52-84) and 54% (95% CI: 41-64) among children and those 65 years and older, respectively. All-age A(H1N1)pdm09 VE against clade 5a.2a was 41% (95% CI: 24-54) and -11% (95% CI: -69 to 26) against clade 5a.2a.1. The A(H3N2) VE was 35% (95% CI: 20-48) among all ages and ranged between 34% and 40% by age group. All-age VE against clade 2a.3a.1 was 38% (95% CI: 1-62). All-age VE against B/Victoria was 83% (95% CI: 65-94), ranging between 70 and 92% by age group.DiscussionThe 2023/24 VEBIS primary care VE against medically attended symptomatic influenza infection was high against influenza B/Victoria, but lower against influenza A(H1N1)pdm09 and A(H3N2). Clade- and age-specific effects may have played a role in the lower A(H1N1)pdm09 VE.

Similares en LA Referencia